Biological studies on the crucial role of curcumin, piperine and taurine combination in the management of patients with hepatocellular carcinoma / (Record no. 173933)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06324namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250929121249.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250909s2024 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 660.6 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 660.6 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.12.25.Ph.D.2024.Ra.B |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Reham Ahmed Abd El Rahiem, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Biological studies on the crucial role of curcumin, piperine and taurine combination in the management of patients with hepatocellular carcinoma / |
| Statement of responsibility, etc. | by Reham Ahmed Abd El Rahiem ; Supervisor Prof.Dr. Emad Mahmud El- Zayat, Prof.Dr. Sherif Abdelaziz Ibrahim, Prof.Dr. Motawa Eissa El Houseini, Prof.Dr. Amr Mahmoud Ismail. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | دراسات بيولوجية على الدور الهام لمزيج الكركمين و البيبرين و التورين فى علاج مرضى سرطان الكبد |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 138 pages : |
| Other physical details | illustrations ; |
| Dimensions | 30 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2024. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 87-138. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Background: Diagnosis of the majority of hepatocellular carcinoma (HCC) patients occurs at intermediate to advanced stages, with a few curative therapeutic options being available. It is therefore strongly urgent to discover additional adjuvant therapy for this lethal malignancy. This study aimed to assess the effectiveness of curcumin (C), piperine (P) and taurine (T) combination as adjuvant agents on serum levels of IFN-γ, immunophenotypic and molecular characterization of mononuclear leukocytes (MNLs) in HCC patients treated with tran-sarterial chemoembolization (TACE). Patients and methods: Serum and MNLs were collected from 20 TACE-treated HCC patients before (baseline-control samples) and after treatment with 5 g curcumin capsules,<br/>10 mg piperine and 0.5 mg taurine taken daily for three consecutive months. Immunophenotypic and molecular characterization of MNLs were determined by flow cytometry and quantitative real time PCR, respectively. In addition, serum IFN-γ level was quantified by ELISA. Results: After receiving treatment with CPT combination, there was a highly significant increase in IFN- γ levels in the sera of patients when compared to basal line control samples. Additionally, the group receiving combined therapy demonstrated a downregulation in the expression levels of PD-1, in MNLs as compared to controls. MNLs' immunophenotyping revealed a significant decline in CD4+CD25+cells (regulatory T lymphocytes). Furthermore, clinicopathological characteristics revealed a highly significant impact of CPT combination on aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and alpha feto protein (AFP) levels. Conclusion: This study introduces a promising adjuvant CPT combined treatment as natural agents to enhance the management of HCC patients who are candidates to TACE treatment. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | الخلفية: يتم تشخيص معظم مرضى سرطان الخلايا الكبدية (HCC) في مراحل متوسطة إلى متقدمة، مع توفر عدد قليل من الخيارات العلاجية. لذلك، من الضروري بشكل ملح تقديم علاجات مساعدة إضافية لهذه الأورام الخبيثة القاتلة. هدفت هذه الدراسة: إلى تقييم فعالية تركيبة الكركمين (C)، والبيبرين(P) ، والتورين (T) كوكلاء مساعدة على مستويات السيرم انترفيرون جاما (IFN-γ) ، والتوصيف المناعي والجزيئي للخلايا اللمفاوية الوحيدة النواة (MNLs) في مرضى HCC الذين يتلقون علاجالحقن الكيماوى عبر الشريان التاجى .(TACE) المرضى والطرق: تم جمع السيرم والخلايا الليمفاوية وحيدة النواة (MNLs) من 20 مريضًا ب HCC تم علاجهم ب TACE قبل العلاج وبعد العلاج بكبسولات الكركمين 5 جم والبيبرين 10 ملغ والتورين 0.5 ملغ يوميًا لمدة ثلاثة أشهر متتالية. تم تحديد التوصيف المناعي والجزيئي لـ MNLs باستخدام تقنية ال Flowcytometry و RT-PCR، على التوالي. بالإضافة إلى ذلك، تم قياس مستوى الانترفيرون-جاما ) IFN-γ ( في السيرم بواسطة تقنيةELISA . النتائج: بعد تلقي العلاج بتركيبةCPT ، كان هناك زيادة ملحوظة لمستويات IFN-γ في سيرم المرضى مقارنة بما قبل العلاج. بالإضافة إلى ذلك، أظهرت المجموعة التي تتلقى العلاج المركب تنظيمًا منخفض في مستويات التعبير عن PD-1 في MNLs مقارنة بالمجموعة المحكمة. كشف التوصيف المناعي لـ MNLs عن انخفاض ملحوظ في الخلايا .CD4+CD25+علاوة على ذلك، كشفت الخصائص العيادية والمرضية عن تأثير ملحوظ لتركيبة CPTعلى مستوياتAST ، LDH، و.AFP الاستنتاج: تقدم هذه الدراسة علاجًا مساعدًا واعدًا بتركيبة CPT لتعزيز إدارة مرضى HCC الذين يُعالجون ب.TAC |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biotechnology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | الكيمياء الحيوية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Hepatocellular carcinoma |
| -- | TACE |
| -- | Curcumin |
| -- | Piprine |
| -- | Taurine |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Emad Mahmud El- Zayat |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sherif Abdelaziz Ibrahim |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Motawa Eissa El Houseini |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Amr Mahmoud Ismail |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2024 |
| Supervisory body | Emad Mahmud El- Zayat |
| -- | Sherif Abdelaziz Ibrahim |
| -- | Motawa Eissa El Houseini |
| -- | Amr Mahmoud Ismail |
| Universities | Cairo University |
| Faculties | Faculty of Science |
| Department | Department of Biotechnology |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 09.09.2025 | 91992 | Cai01.12.25.Ph.D.2024.Ra.B | 01010110091992000 | 09.09.2025 | 09.09.2025 | Thesis |